Please assess the completion status of the following clinical trial:

Trial Title: PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Main Inclusion Criteria:~* Operable colon cancer amenable to curative surgery.~* Performance status of 0 to 1~* Informed consent form~* Patients must be at least 18 years of age.~Main Exclusion Criteria:~* Any concurrent other anti-tumor therapy~* Any prohibited concomitant medication within 30 days of surgery~* Pregnancy or breast-feeding.~* Second primary malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levoleucovorin 200 mg/m2 (Type: ACTIVE_COMPARATOR): One i.v. bolus injection of study drug after the patient has been anaesthetized.
- Levoleucovorin 60 mg/m2 (Type: ACTIVE_COMPARATOR): One i.v. bolus injection of study drug after the patient has been anaesthetized.
- 6R-MTHF 200 mg/m2 (Type: EXPERIMENTAL): One i.v. bolus injection of study drug after the patient has been anaesthetized.
- 6R-MTHF 60 mg/m2 (Type: EXPERIMENTAL): One i.v. bolus injection of study drug after the patient has been anaesthetized.

Based on this trial design, predict the completion outcome and termination type (if applicable).